Secora Michael's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Feb 15, 2024
- Accession no.
- 0001209191-24-003410
- Filed
- Feb 15, 2024
- Trade date
- Feb 13-14, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $507.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Secora MichaelCIK 0001855980 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | Class A Common Stock | MOption exerciseAcquired | +37,500 | $2.22 | +$83,250 | 1,198,851 | Direct | |
| Feb 13, 2024 | Class A Common Stock | SSaleDisposed | −25,000 | $9.86F2 | −$246,500 | 1,173,851 | Direct | |
| Feb 14, 2024 | Class A Common Stock | MOption exerciseAcquired | +37,500 | $2.22 | +$83,250 | 1,211,351 | Direct | |
| Feb 14, 2024 | Class A Common Stock | SSaleDisposed | −23,933 | $10.43F3 | −$249,621.19 | 1,187,418 | Direct | |
| Feb 14, 2024 | Class A Common Stock | SSaleDisposed | −1,067 | $10.98F4 | −$11,715.66 | 1,186,351 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | Class A Common Stock | MOption exerciseDisposed | −37,500 | $0.00 | $0 | 997,635 | Direct | |
| Feb 14, 2024 | Class A Common Stock | MOption exerciseDisposed | −37,500 | $0.00 | $0 | 960,135 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $9.635 to $10.16 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $9.92 to $10.905. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $10.925 to $11.015. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.